Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Free Cash Flow for 14 consecutive years, with -$198.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 18.56% year-over-year to -$198.0 million; the TTM figure through Mar 2026 stood at -$503.0 million (down 24.51% YoY), while the FY2025 annual figure was -$472.0 million, down 10.02% from the prior year.
• Free Cash Flow fell to -$198.0 million in Q1 2026 per RARE's latest filing, from -$100.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$51.4 million in Q4 2023 and bottomed at -$198.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$122.4 million across 5 years, with a median of -$111.5 million in 2025.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 1041.85% — and 2023, when it surged 72.35%.
• Ultragenyx Pharmaceutical's Free Cash Flow stood at -$186.0 million in 2022, then soared by 72.35% to -$51.4 million in 2023, then slumped by 70.09% to -$87.5 million in 2024, then fell by 15.19% to -$100.8 million in 2025, then tumbled by 96.49% to -$198.0 million in 2026.
• Business Quant data shows RARE's Free Cash Flow at -$198.0 million in Q1 2026, -$100.8 million in Q4 2025, and -$92.7 million in Q3 2025.